Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Changtai Granules is a Traditional Chinese Medicine (TCM) compound developed by the Second Military Medical University (SMMU), specifically within the Department of Gastroenterology at Changhai Hospital. It is primarily indicated for the treatment of ulcerative colitis (UC), particularly for patients presenting with damp-heat and spleen deficiency patterns. The formulation is a complex mixture of herbal extracts, typically including *Astragalus membranaceus* (Huangqi), *Coptis chinensis* (Huanglian), *Sanguisorba officinalis* (Diyu), *Curcuma wenyujin* (Yujin), and *Paeonia lactiflora* (Baishao). Its mechanism of action involves the suppression of intestinal inflammation through the inhibition of the NF-κB signaling pathway and the subsequent downregulation of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Clinical studies conducted in China have demonstrated its efficacy in inducing clinical remission and promoting mucosal healing in patients with mild-to-moderate ulcerative colitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fufang changtai granules.